Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.69 |
| ▸ | AURKA | O14965 | 3/20 | 0.69 |
| ▸ | GSK3A | P49840 | 3/20 | 0.69 |
| ▸ | IGF1R | P08069 | 6/20 | 0.67 |
| ▸ | CDK2 | P24941 | 5/20 | 0.62 |
| ▸ | CDK4 | P11802 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.59 |
| ▸ | CDK1 | P06493 | 4/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | SYK | P43405 | 3/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260092 | 0.83 | GSK3B (0.71) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL4459525 | 0.82 | IGF1R (1.00) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL5262378 | 0.81 | GSK3B (1.00) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL7236862 | 0.81 | GSK3B (0.68) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL3270075 | 0.79 | IGF1R (0.82) | GSK3BAURKAIGF1RCDK2CDK4 | |
| SCHEMBL3271930 | 0.79 | CDK2 (0.69) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL6701811 | 0.79 | GSK3B (0.64) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL6642260 | 0.78 | IGF1R (0.62) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL5261726 | 0.78 | IGF1R (0.85) | GSK3BAURKAGSK3AIGF1RCDK2 | |
| SCHEMBL6641459 | 0.78 | CDK2 (0.79) | GSK3BAURKAGSK3AIGF1RCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | claimed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | claimed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | claimed |
| EP-1278735-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001064656-A1 | 2,4,DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | GSK3B 572/4885AURKA 251/4885GSK3A 701/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | GSK3B 568/4885AURKA 247/4885GSK3A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.